Immutep (IMMP) has released an update.
Immutep Limited has initiated a Phase I clinical trial of IMP761, a pioneering LAG-3 agonist antibody aimed at treating autoimmune diseases by modulating the immune system. The trial, which is being conducted in the Netherlands, will assess the safety and efficacy of the drug in 49 healthy volunteers, with safety results expected by the end of the year and further pharmacokinetic and pharmacodynamic data by the first half of 2025. Early research suggests that IMP761 could significantly reduce inflammatory responses and help manage autoimmune conditions like rheumatoid arthritis and Type 1 diabetes.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
